INHIBRX BIOSCIENCES Trademark

Trademark Overview


On Friday, March 8, 2024, a trademark application was filed for INHIBRX BIOSCIENCES with the United States Patent and Trademark Office. The USPTO has given the INHIBRX BIOSCIENCES trademark a serial number of 98440219. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, November 12, 2024. This trademark is owned by INHIBRX, INC.. The INHIBRX BIOSCIENCES trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances used for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Genetically engineered proteins for diagnostic purposes; Gene proteins, namely, antibodies and fusion proteins for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Pharmaceutical substances and preparations namely, genetically engineered proteins for medical diagnostic use; Biochemicals, namely, engineered proteins for the regulation of animal, plant, viral and microbial genes for clinical and medical laboratory use in human and animal therapeutics for the treatment and diagnostic of cancer, autoimmune disorders, and inflammatory diseases and conditions
inhibrx biosciences

General Information


Serial Number98440219
Word MarkINHIBRX BIOSCIENCES
Filing DateFriday, March 8, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, November 12, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 12, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances used for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Genetically engineered proteins for diagnostic purposes; Gene proteins, namely, antibodies and fusion proteins for the treatment of cancer, autoimmune disorders, and inflammatory diseases and conditions; Pharmaceutical substances and preparations namely, genetically engineered proteins for medical diagnostic use; Biochemicals, namely, engineered proteins for the regulation of animal, plant, viral and microbial genes for clinical and medical laboratory use in human and animal therapeutics for the treatment and diagnostic of cancer, autoimmune disorders, and inflammatory diseases and conditions
NOT AVAILABLE"BIOSCIENCES"

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 8, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameINHIBRX BIOSCIENCES, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLA JOLLA, CA 92037

Party NameINHIBRX BIOSCIENCES, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressLA JOLLA, CA 92037

Party NameINHIBRX, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLa Jolla, CA 92037

Trademark Events


Event DateEvent Description
Friday, March 8, 2024NEW APPLICATION ENTERED
Friday, March 8, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 13, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Friday, September 20, 2024ASSIGNED TO EXAMINER
Wednesday, October 2, 2024EXAMINERS AMENDMENT E-MAILED
Wednesday, October 2, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, October 2, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 2, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, October 2, 2024EXAMINER'S AMENDMENT ENTERED
Wednesday, October 23, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 12, 2024PUBLISHED FOR OPPOSITION
Tuesday, November 12, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED